| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/10/1999 | CA2236493A1 Mura |
| 01/10/1999 | CA2236485A1 Novel 1spa |
| 01/09/1999 | CA2208924A1 Sparing paclitaxel by the use of hyaluronan |
| 01/08/1999 | CA2236473A1 Novel pcra |
| 01/08/1999 | CA2236468A1 Novel use |
| 01/07/1999 | WO1999000518A1 Member of the tnf family useful for treatment and diagnosis of disease |
| 01/07/1999 | WO1999000507A1 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase from human |
| 01/07/1999 | WO1999000498A1 Human nk-3 related prostate specific gene-1 |
| 01/07/1999 | WO1999000494A2 Cell activation process and reagents therefor |
| 01/07/1999 | WO1999000422A1 Novel family of pheromone receptors |
| 01/07/1999 | WO1999000421A1 Site-directed chemotherapy of metastases |
| 01/07/1999 | WO1999000144A1 Thermodynamic adaptive phased array system for activating thermosensititve liposomes in targeted drug delivery |
| 01/07/1999 | WO1999000140A2 Accelerating animal hoof growth with somatotropin |
| 01/07/1999 | WO1999000137A2 Induction of an activated myeloid dendritic cell phenotype |
| 01/07/1999 | WO1999000136A1 Control of acidic gut syndrome |
| 01/07/1999 | WO1999000133A1 Method for optimizing retinal and optic nerve health |
| 01/07/1999 | WO1999000132A1 Use of phospholamban inhibitors for increasing coronary flow |
| 01/07/1999 | WO1999000129A1 Calcium blockers to treat proliferative vitreoretinopathy |
| 01/07/1999 | WO1999000123A1 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
| 01/07/1999 | WO1999000115A1 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases |
| 01/07/1999 | WO1999000112A1 Sucralfate-containing composition and process for the preparation thereof |
| 01/07/1999 | WO1998046270A3 Polymeric conjugates polyvalently presenting an agent for therapy |
| 01/07/1999 | WO1998045427A3 Insulin-like growth factor agonist peptides |
| 01/07/1999 | WO1998044893A3 Method and formulation for treating vascular disease |
| 01/07/1999 | WO1998035048A3 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 01/07/1999 | EP0889132A2 Streptococcus pneumoniae gidA2 polynucleotides and polypeptides |
| 01/07/1999 | EP0889131A2 Staphylococcus aureus gidA2 polynucleotides and polypeptides |
| 01/07/1999 | EP0889130A2 GidB polypeptides from Streptococcus pneumoniae |
| 01/07/1999 | EP0889129A2 GidA1 polypeptides from Staphylococcus aureus |
| 01/07/1999 | EP0889128A2 midA1 polypeptides from Streptococcus pneumoniae |
| 01/07/1999 | EP0889123A2 MurC gene of Staphylococcus aureus coding for UDP-N-acetylmuramate:L-alanine Ligase |
| 01/07/1999 | EP0888377A1 MURINE $g(a)(1,3)FUCOSYLTRANSFERASE Fuc-TVII, DNA ENCODING THE SAME, METHOD FOR PREPARING THE SAME, ANTIBODIES RECOGNIZING THE SAME, IMMUNOASSAYS FOR DETECTING THE SAME, PLASMIDS CONTAINING SUCH DNA, AND CELLS CONTAINING SUCH A PLASMID |
| 01/07/1999 | EP0888375A1 A novel disintegrin metalloprotease and methods of use |
| 01/07/1999 | EP0888352A1 Fused imidazole derivatives as multidrug resistance modulators |
| 01/07/1999 | EP0888278A1 Antidiabetic agents |
| 01/07/1999 | EP0888138A1 Topical formulations for the treatment of nail psoriasis |
| 01/07/1999 | EP0888128A2 Delivery of exogenous compounds |
| 01/07/1999 | EP0888127A1 Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
| 01/07/1999 | EP0888123A2 Antagonism of endothelin actions |
| 01/07/1999 | EP0888121A1 Use of vasopressin receptor antagonist for regulation of acth release |
| 01/07/1999 | EP0854713A4 Compositions of melatonin and analgetic agents and methods of use thereof |
| 01/07/1999 | EP0386117B1 Treating premenstrual or late luteal phase syndrome |
| 01/07/1999 | CA2295747A1 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
| 01/07/1999 | CA2295311A1 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase from human |
| 01/07/1999 | CA2295303A1 Human nk-3 related prostate specific gene-1 |
| 01/07/1999 | CA2295229A1 Induction of an activated myeloid dendritic cell phenotype |
| 01/07/1999 | CA2295098A1 Calcium blockers to treat proliferative vitreoretinopathy |
| 01/07/1999 | CA2295089A1 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases |
| 01/07/1999 | CA2294904A1 Control of acidic gut syndrome |
| 01/07/1999 | CA2294550A1 Use of phospholamban inhibitors for increasing coronary flow |
| 01/07/1999 | CA2294473A1 Novel family of pheromone receptors |
| 01/07/1999 | CA2294343A1 Method for optimizing retinal and optic nerve health |
| 01/07/1999 | CA2294131A1 Site-directed chemotherapy of metastases |
| 01/07/1999 | CA2292379A1 Member of the tnf family useful for treatment and diagnosis of disease |
| 01/06/1999 | CN1204264A Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and kappa-2 opioid agonist |
| 01/05/1999 | US5856364 Mixture of pyruvate salt, antioxidant and fatty acid |
| 01/05/1999 | US5856360 Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| 01/05/1999 | US5856357 Method for treating wrinkles using certain alpha hydroxyacids |
| 01/05/1999 | US5856342 Combination of a β-receptor blocker and a local anaesthetic |
| 01/05/1999 | US5856162 Receptor-type phosphotyrosine phosphatase-κ |
| 01/05/1999 | US5856133 G-beta-gamma regulated phosphatidylinositol-3'kinase |
| 01/05/1999 | US5856132 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 01/05/1999 | US5856129 Hydridized detector |
| 01/05/1999 | US5856098 Detection of this receptor variant in cells of obese individuals, and methods for treating obesity by targeting variant. |
| 01/05/1999 | US5855987 Bioactive conjugates of cellulose with amino compounds |
| 01/05/1999 | US5855907 Method of treatment of migraine |
| 01/05/1999 | US5855866 Constructs designed to have a cytotoxic or otherwise anticellular effect against tumor vasculature |
| 01/03/1999 | CA2236462A1 Murc |
| 01/03/1999 | CA2208916A1 Promotion of wound healing utilizing steroids having reduced deterioroussystemic side effects typical of glucocorticoids, mineralocorticoids andsex steroids |
| 01/01/1999 | CA2236459A1 Novel compounds |
| 01/01/1999 | CA2236452A1 Gida1 |
| 01/01/1999 | CA2236441A1 Gida2 |
| 01/01/1999 | CA2236435A1 Gida2 |
| 01/01/1999 | CA2236425A1 Gida1 |
| 12/30/1998 | WO1998058948A1 Tartrate salt of a substituted dipeptide as growth hormone secretagogue |
| 12/30/1998 | WO1998058947A1 Dipeptide derivatives as growth hormone secretagogues |
| 12/30/1998 | WO1998058676A1 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
| 12/30/1998 | WO1998058675A1 Pharmaceutical composition with antiviral activity containing an hydroxymic acid derivative and an antiviral agent |
| 12/30/1998 | WO1998058672A1 Cd154 blockade therapy for therapeutic protein inhibitor syndrome |
| 12/30/1998 | WO1998058658A1 Therapeutic method for management of diabetes mellitus |
| 12/30/1998 | WO1998058646A1 Use of somatostatin agonists and antagonists for treating diseases related to the eye |
| 12/30/1998 | WO1998058638A1 Method of treating heart failure |
| 12/30/1998 | WO1998058636A1 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| 12/30/1998 | WO1998058633A2 Microdose therapy of vascular conditions by no donors |
| 12/30/1998 | WO1998058629A2 Preparation of pharmaceutical compositions |
| 12/30/1998 | WO1998058588A1 Methods and devices for providing acoustic hemostasis |
| 12/30/1998 | EP0887416A2 Human AFC1 |
| 12/30/1998 | EP0887415A2 Human RCE1 |
| 12/30/1998 | EP0887413A2 Histidine kinase |
| 12/30/1998 | EP0887411A2 N-acetylglucosamine-1-phosphate uridyltransferase (GlmU) from Streptococcus pneumoniae |
| 12/30/1998 | EP0887408A1 Wnt-3 oncogene: polypeptides and polynucleotides |
| 12/30/1998 | EP0887407A2 cDNA clone HAPO167 that encodes a human 7-transmembrane receptor |
| 12/30/1998 | EP0887406A2 A member of the FRZB family, franzzled |
| 12/30/1998 | EP0887081A2 Human serum glucocorticoid regulated kinase, a target for chronic renal disease |
| 12/30/1998 | EP0887076A2 Adhesion prevention and an endoscopic insufflation system therefor |
| 12/30/1998 | EP0886677A1 Combinations of fungal cell wall degrading enzyme and fungal cell membrane affecting compound |
| 12/30/1998 | EP0886649A1 Protein occlusion for delivery of small molecules |
| 12/30/1998 | EP0886646A1 Novel compounds |
| 12/30/1998 | EP0886526A1 Protection of hemopoietic cells |
| 12/30/1998 | EP0886525A1 PROGRAMMED CELL DEATH AND INTERLEUKIN-1$g(b) |